[3]
World Health Organization. First WHO ministerial conference on
global action against dementia: Meeting report. WHO Headquarters
Geneva, Switzerland;. 2015.
[4]
Winblad B, Amouyel P, Andrieu S, et al. Defeating alzheimer’s disease and other dementias: A priority for European science and society. Lancet Neurol 2016; 15(5): 455-532.
[5]
Doraiswamy PM, Steffens DC. Combination therapy for early Alzheimer’s disease: What are we waiting for? J Am Geriatr Soc 1998; 46(10): 1322-4.
[6]
Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet 2017; 390(10113): 2673-734.
[7]
Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomized controlled trial. Lancet 2015; 385(9984): 2255-63.
[8]
Bachurin S, Gavrilova S, Samsonova A, et al. Mild cognitive impairment due to alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention. Pharmacol Res 2017; 129: 216-26.
[9]
Moreno-Grau S, Rodriguez-Gomez O, Sanabria A, et al. Exploring APOE genotype effects on Alzheimer’s disease risk and amyloid β burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results. Alzheimers Dementia J Alzheimers Assoc 2017; 14(5): 634-43.
[10]
Seifan A, Isaacson R. The alzheimer’s prevention clinic at Weill Cornell medical college/ New-York Presbyterian hospital: Risk stratification and personalized early intervention. J Prev Alzheimers Dis 2015; 2(4): 254-66.
[11]
Kane RL, Butler M, Fink HA, et al. Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer’s-Type Dementia Rockville, MD. Agency for Healthcare Research and Quality (US); 2017.
[12]
Cummings JL, Isaacson RS, Schmitt FA, et al. A practical algorithm for managing Alzheimer’s disease: What, when, and why? Ann Clin Transl Neurol 2015; 2(3): 307-23.
[13]
Østergaard SD, Mukherjee S, Sharp SJ, et al. Associations between potentially modifiable risk factors and Alzheimer disease: A Mendelian randomization study. PLoS Med 2015; 12(6): e1001841.
[14]
Stephenson D, Perry D, Bens C, et al. Charting a path toward combination therapy for Alzheimer’s disease. Expert Rev Neurother 2015; 15(1): 107-13.
[15]
Xu W, Tan L, Wang HF, et al. Meta-analysis of modifiable risk factors for Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2015; 86: 1284-5.
[16]
Norton S, Matthews FE, Barnes DE, et al. Potential for primary prevention of Alzheimer’s disease: An analysis of population-based data. Lancet Neurol 2014; 13(8): 788-94.
[17]
Morris MC, Tangney CC, Wang Y, et al. MIND diet associated with reduced incidence of Alzheimer’s disease. J Alzheimers Dement 2015; 11(9): 1007-14.
[18]
Paddock CP. Concussion linked to brain changes in people at genetic risk for Alzheimer’s. Medical News Today 2017.
[19]
Joubert LM, Manore M. Exercise, nutrition, and homocysteine. Int J Sport Nutr Exerc Metab 2006; 16(4): 341-61.
[20]
Rodrigue KM, Rieck JR, Kennedy KM, et al. Risk factors for β-Amyloid deposition in healthy aging: Vascular and genetic effects. JAMA Neurol 2013; 70(5): 600-6.
[21]
Hong H, Kim BS, Im H. Pathophysiological role of neuroinflammation in neurodegenerative diseases and psychiatric disorders. Int Neurol J 2016; 20(Suppl. 1): S2-7.
[22]
Chaker L, Wolters F, Korevaar TI, et al. Thyroid function and the risk of dementia: The rotterdam study. Neurology 2016; 87(16): 1688-95.
[24]
Chatterjee S, Peters SAE, Woodward M, et al. Type 2 Diabetes as a risk factor for dementia in women compared with men: A pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care 2016; 39(2): 300-7.
[25]
Bucossi S, Ventriglia M, Panetta V, et al. Copper in alzheimer’s disease: A Meta-analysis of serum, plasma, and cerebrospinal fluid studies. J Alzheimers Dis 2011; 24(1): 175-85.
[27]
Lövheim H, Gilthorpe J, Adolfsson R, et al. Reactivated herpes simplex infection increases the risk of Alzheimer’s disease. Alzheimers Dement 2015; 11(6): 593-9.
[28]
Lovheim H, Gilthorpe J, Johansson A, et al. Herpes simplex infection and the risk of Alzheimer’s disease- A nested case-control study. Alzheimers Dement 2015; 11(6): 587-92.
[29]
Itzhaki RF, Lathe R, Balin BJ, et al. Microbes and Alzheimer’s disease. J Alzheimers Dis 2016; 51(4): 979-84.
[30]
Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer’s disease. Trends Neurosci 2008; 31(19): 454-63.
[31]
Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: A clinical review. Clin Interv Aging 2009; 4: 225-33.
[32]
Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 2008; 56(12): 2203-10.
[33]
Hirai K, Aliev G, Ninomura A, et al. Mitochondrial abnormalities in alzheimer’s disease. J Neurosci 2001; 21(9): 3017-23.
[35]
Xu W, Tan L, Wang H, et al. Meta-analysis of modifiable risk factors for Alzheimer’s disease. Cognitive Neurol 2015; 86(12): 1299-306.
[36]
Chakrabarti S, Khemka V, Banerjee A, et al. Metabolic risk factors of sporadic alzheimer’s disease: Implications in the Pathology, Pathogenesis and Treatment. Aging Dis 2015; 6(4): 282-99.
[37]
Cerutti-Kopplin D, Feine J, Padilha DM, et al. Tooth Loss Increases the Risk of Diminished Cognitive Function: A Systematic Review and Meta-analysis. JDR Clin Trans Res 2016; 10-9.
[38]
Last W. Health Science. [Online]. 2016 [cited 2017]. Available
from: www.health¬science-spirit.com\pyroluria.htm.
[39]
Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science 2013; 342(6156): 373-.
[40]
Ferreira LK, Tamashiro-Duran JH, Squarzoni P, et al. The link between cardiovascular risk, Alzheimer’s disease, and mild cognitive impairment: Support from recent functional neuroimaging studies. Br J Psychiatry 2014; 36(4): 344-57.
[41]
Kim HA, Miller AA, Drummond GR, et al. Vascular cognitive impairment and Alzheimer’s disease: Role of cerebral hypoperfusion and oxidative stress. Naunyn Schmiedebergs Arch Pharmacol 2012; 385(10): 953-9.
[43]
Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2015; 53(4): 695-9.
[44]
Scharre DW, Chang SI, Murden RA, et al. Self-administered Gerocognitive Examination (SAGE): A brief cognitive assessment Instrument for Mild Cognitive Impairment (MCI) and early dementia. Alzheimer Dis Assoc Disord 2010; 24(1): 64-71.
[45]
Gualtieri CT, Johnson LG. Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs. Arch Clin Neuropsychol 2006; 21(7): 623-43.
[46]
Galvin J. The prevention of alzheimer’s disease: Lessons learned and applied. J Am Geriatr Soc 2017; 65(10): 2128-33.
[47]
Isaacson R. Is alzheimer’s prevention possible? J Am Geriatr Soc 2017; 65(10): 2153-4.
[50]
Scharre D, Chang S, Nagaraja H, et al. Longitudinal Changes in Self-Administered Gerocognitive Examination (SAGE) and Mini-Mental State Exam (MMSE) Score for Subjective Cognitive Impairment (SCI), Mild Cognitive Impairment (MCI), Dementia Converters, and Alzheimer’s Disease (AD) Patients. Alzheimers Dement J Alzheimers Assoc 2015; 11(7): 570.